Early trial tests new Weight-Loss Drug's safety
NCT ID NCT06557356
Summary
This early-stage study tested the safety and side effects of an experimental drug called LY3532226 in 132 adults with obesity. Researchers gave participants either the drug or a placebo weekly or monthly and measured how much medication entered their bloodstream and how long it stayed. The main goal was to understand if the drug was safe and well-tolerated before testing its effectiveness for weight loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
-
Fortrea Clinical Research Unit
Madison, Wisconsin, 53704, United States
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
Conditions
Explore the condition pages connected to this study.